Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
F Yu, C Zhu, S Ze, H Wang, X Yang, M Liu… - Journal of Medicinal …, 2022 - ACS Publications
Journal of Medicinal Chemistry, 2022•ACS Publications
In recent years, the adenosine A2A receptor (A2AR) has shown exciting progress in the
development of immunotherapies for the treatment of cancer. Herein, a 2-amino-7, 9-dihydro-
8 H-purin-8-one compound (1) was identified as an A2AR antagonist hit through in-house
library screening. Extensive structure–activity relationship (SAR) studies led to the discovery
of 2-aminopteridin-7 (8 H)-one derivatives, which showed high potencies on A2AR in the
cAMP assay. Compound 57 stood out with an IC50 value of 8.3±0.4 nM against A2AR at the …
development of immunotherapies for the treatment of cancer. Herein, a 2-amino-7, 9-dihydro-
8 H-purin-8-one compound (1) was identified as an A2AR antagonist hit through in-house
library screening. Extensive structure–activity relationship (SAR) studies led to the discovery
of 2-aminopteridin-7 (8 H)-one derivatives, which showed high potencies on A2AR in the
cAMP assay. Compound 57 stood out with an IC50 value of 8.3±0.4 nM against A2AR at the …
In recent years, the adenosine A2A receptor (A2AR) has shown exciting progress in the development of immunotherapies for the treatment of cancer. Herein, a 2-amino-7,9-dihydro-8H-purin-8-one compound (1) was identified as an A2AR antagonist hit through in-house library screening. Extensive structure–activity relationship (SAR) studies led to the discovery of 2-aminopteridin-7(8H)-one derivatives, which showed high potencies on A2AR in the cAMP assay. Compound 57 stood out with an IC50 value of 8.3 ± 0.4 nM against A2AR at the 5′-N-ethylcarboxamidoadenosine (NECA) level of 40 nM. The antagonistic effect of 57 was sustained even at a higher NECA concentration of 1 μM, which mimicked the adenosine level in the tumor microenvironment (TME). Importantly, 57 enhanced T cell activation in both the IL-2 production assay and the cancer-cell-killing model, thus demonstrating its potential as a lead for developing novel A2AR antagonists in cancer immunotherapy.
ACS Publications